Back to top
more

Zymeworks (ZYME)

(Real Time Quote from BATS)

$8.80 USD

8.80
128,397

+0.13 (1.50%)

Updated Apr 19, 2024 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ZYME

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Zymeworks Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 374 492 253 426 299
Receivables 19 33 16 15 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 19 19 20 13 11
Total Current Assets 413 545 288 455 312
Net Property & Equipment 20 25 23 12 11
Investments & Advances 82 1 1 26 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 4 1 4 3 2
Intangibles 20 21 16 17 18
Deposits & Other Assets 25 33 30 20 20
Total Assets 581 649 389 538 368
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 45 87 63 44 36
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 2 1 0 0 0
Other Current Liabilities 5 4 8 39 46
Total Current Liabilities 56 96 72 86 83
Mortgages 0 0 0 0 0
Deferred Taxes/Income 36 32 35 34 33
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 3 3 3 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 116 156 140 128 123
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1,007 907 741 724 450
Capital Surplus 142 152 198 164 93
Retained Earnings -677 -559 -683 -471 -291
Other Equity -7 -7 -7 -7 -7
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 465 493 249 410 246
Total Liabilities & Shareholder's Equity 581 649 389 538 368
Total Common Equity 465 493 249 410 246
Shares Outstanding 70.10 63.00 46.50 45.80 39.50
Book Value Per Share 6.63 7.82 5.36 8.95 6.22

Fiscal Year End for Zymeworks Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 374 295 340 341
Receivables NA 19 67 49 67
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 19 12 31 19
Total Current Assets NA 413 375 420 426
Net Property & Equipment NA 20 21 22 24
Investments & Advances NA 82 96 92 72
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 4 1 1 1
Intangibles NA 20 20 19 20
Deposits & Other Assets NA 25 26 26 35
Total Assets NA 581 556 602 601
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 45 68 70 59
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 2 1 1 1
Other Current Liabilities NA 5 0 19 4
Total Current Liabilities NA 56 73 94 67
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 36 35 33 32
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2 4 4
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 116 132 153 127
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1,007 941 939 910
Capital Surplus NA 142 154 152 153
Retained Earnings NA -677 -663 -634 -583
Other Equity NA -7 -8 -8 -6
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 465 424 449 474
Total Liabilities & Shareholder's Equity NA 581 556 602 601
Total Common Equity 0 465 424 449 474
Shares Outstanding 70.50 70.10 67.90 64.10 64.10
Book Value Per Share 0.00 6.63 6.25 7.00 7.39